Novartis Says MS Pill Helped Control Disease With Favorable Safety Data in Trials
By Adria Calatayud
Novartis said its experimental multiple sclerosis pill achieved a significant reduction in symptom flare-ups in the most common form of the disease with a favorable safety profile in two late-stage studies.
The Swiss drugmaker said Friday that the studies showed its medicine--known as remibrutinib and marketed as Rhapsido for a skin condition--achieved reductions in the annualized relapse rate of 35.2% and 31.2% compared with Sanofi's Aubagio, meeting the primary goal of both trials.
This translated into one relapse every 13 years, the company said.
No liver safety signal was observed, Novartis said.
Novartis Chief Medical Officer Shreeram Aradhye said the study results point to the drug's potential to support long-term disease management by combining high efficacy with a favorable safety profile.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 23, 2026 12:20 ET (16:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States